Cholera Vaccines Market by Product Type, Distribution Channel, End User 2024-2032

1
Global Cholera Vaccines Market Research and
Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• International Market Analysis Research and
  Consulting Group is a leading adviser on
  management strategy and market research
  worldwide. We partner with clients in all regions
  and industry verticals to identify their
  highest-value opportunities, address their most
  critical challenges, and transform their
  businesses.
• IMARCs information products include major
  market, scientific, economic and technological
  developments for business leaders in
  pharmaceutical, industrial, and high technology
  organizations. Market forecasts and industry
  analysis for biotechnology, advanced materials,
  chemicals, food and beverage, travel and tourism,
  nanotechnology and novel processing methods are
  at the top of the companys expertise.
• IMARCs tailored approach combines unfathomable
  insight into the dynamics of companies and
  markets with close cooperation at all levels of
  the client organization. This ensures that our
  clients achieve unmatchable competitive
  advantage, build more proficient organizations,
  and secure lasting results.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Cholera Vaccines Market Global Industry
  Trends, Share, Size, Growth, Opportunity and
  Forecast 2024-2032," the global cholera vaccines
  market size reached US 5.4 Million in 2023.
• Factors Affecting the Growth of the Cholera
  Vaccines Industry
• Public Health Demand and Outbreaks
• The growth of the cholera vaccines industry is
  heavily influenced by the frequency and severity
  of cholera outbreaks. Cholera remains a
  significant public health concern in many parts
  of the world, particularly in regions with
  inadequate sanitation and access to clean water.
  The recurring nature of outbreaks in countries
  such as Yemen, Haiti, and several African nations
  underscores the urgent need for effective
  vaccination programs.
• As outbreaks continue to cause high morbidity and
  mortality, especially in vulnerable populations,
  there is a growing demand for preventive
  measures, including vaccines. This demand drives
  investments in vaccine development and
  distribution, fostering industry growth.
  Furthermore, increased awareness and
  prioritization of cholera prevention by global
  health organizations, such as the World Health
  Organization (WHO) and the Global Task Force on
  Cholera Control (GTFCC), bolster the push for
  widespread vaccination efforts.

4
Report Highlight and Description

• Advancements in Vaccine Technology
• Technological advancements play a crucial role in
  the expansion of the cholera vaccines industry.
  Innovations in biotechnology and vaccine delivery
  methods have led to the development of more
  effective and easier-to-administer vaccines. Oral
  cholera vaccines (OCVs), such as Dukoral,
  Shanchol, and Euvichol, have improved
  immunogenicity and can be administered without
  the need for healthcare professionals, making
  mass vaccination campaigns more feasible,
  especially in resource-limited settings.
• Additionally, ongoing research into new vaccine
  candidates and formulations aims to enhance the
  duration of immunity and effectiveness against
  diverse cholera strains. These technological
  improvements enhance the overall efficacy of
  cholera vaccines and reduce production costs and
  logistical challenges, making vaccines more
  accessible and affordable for endemic regions.
• International Funding and Support
• The availability of international funding and
  support is a pivotal factor in the growth of the
  cholera vaccines industry. Large-scale
  vaccination programs require substantial
  financial resources, which are often provided by
  international donors, governments, and
  non-governmental organizations (NGOs).

5
Report Highlight and Description

• Institutions such as Gavi, the Vaccine Alliance,
  and the Bill Melinda Gates Foundation have been
  instrumental in funding cholera vaccination
  initiatives, ensuring the procurement and
  distribution of vaccines to high-risk areas.
  Additionally, coordinated efforts by global
  health bodies to secure vaccine stockpiles and
  respond swiftly to outbreaks have underscored the
  importance of sustained financial commitment.
  Such support facilitates immediate outbreak
  response and aids in long-term planning and
  infrastructure development for routine
  immunization programs. This financial backing is
  essential for maintaining and scaling up
  production capacities, research, and distribution
  networks, ultimately driving the industry's
  growth.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/cholera-vaccines-market
  /requestsample

6
Report Description

• Global Cholera Vaccines Market Trends
• The global cholera vaccines market is witnessing
  significant growth, driven by several key trends.
  Increasing incidence of cholera outbreaks,
  particularly in developing regions, has
  heightened the demand for effective vaccination
  programs. Besides this, ongoing technological
  advancements, such as the development of oral
  cholera vaccines (OCVs) such as Dukoral,
  Shanchol, and Euvichol, have improved
  accessibility and administration, facilitating
  large-scale immunization efforts. Support from
  international organizations, including WHO and
  Gavi, has bolstered funding and distribution,
  ensuring vaccines reach high-risk populations.
• Additionally, there is a growing emphasis on
  preventive healthcare and the integration of
  cholera vaccines into routine immunization
  schedules. Furthermore, collaborative efforts
  between governments, NGOs, and private sector
  players are also driving market expansion.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/cholera-vaccines-market
  

7
Report Segmentation

• Breakup by Vaccine Type
• Whole Cell V. Cholerae O1 with Recombinant
  B-Subunit
• Killed Oral O1 and O139
•  
• Breakup by Product
• Dukoral
• Shanchol
• Vaxchora
• Euvichol and Euvichol-Plus
• Others
• Breakup by End User
• Hospitals and Clinics

8
Report Segmentation

• Research and Academic Laboratories
• Others
• Breakup by Region
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

9
Competitive Landscape with Key Players

• Astellas Pharma Inc.
• Celldex Therapeutics Inc. (Avant
  Immunotherapeutics Inc.)
• Emergent BioSolutions Inc.
• Eubiologics Co. Ltd.
• Johnson Johnson
• Merck Co. Inc.
• Pfizer Inc.
• PharmaChoice Canada Inc.
• Sanofi S.A.
• Takeda Pharmaceutical Company Limited
• Valneva SE

10
Key Questions Answered in the Report
11
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Cholera Vaccines
  Market    5.1    Market Overview    5.2  
   Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by Vaccine Type
• 6.1 Whole Cell V. Cholerae O1 with
  Recombinant B-Subunit
• 6.1.1 Market Trends
• 6.1.2 Market Forecast
• 6.2 Killed Oral O1 and O139
• 6.2.1 Market Trends
• 6.2.2 Market Forecast
• 7 Market Breakup by Product
• 7.1 Dukoral
• 7.1.1 Market Trends
• 7.1.2 Market Forecast       

12
Table of Contents

• 7.2 Shanchol
• 7.2.1 Market Trends
• 7.2.2 Market Forecast
• 7.3 Vaxchora
• 7.3.1 Market Trends
• 7.3.2 Market Forecast
• 7.4 Euvichol and Euvichol-Plus
• 7.4.1 Market Trends
• 7.4.2 Market Forecast
• 7.5 Others
• 7.5.1 Market Trends
• 7.5.2 Market Forecast
• 8 Market Breakup by End User
• 8.1 Hospitals and Clinics
• 8.1.1 Market Trends
• 8.1.2 Market Forecast
• 8.2 Research and Academic Laboratories
• 8.2.1 Market Trends
• 8.2.2 Market Forecast

13
Partial List of Clients
14
Partial List of Clients
15
Disclaimer

• 2024 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

16
Contact Us
Visit us at
https//www.imarcgroup.com
1-631-791-1145
sales_at_imarcgroup.com
Stay With Us